This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Tecarfarin
- DrugBank Accession Number
- DB12823
- Background
Tecarfarin has been used in trials studying the prevention of Thrombosis and Thromboembolism.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Tecarfarin (DB12823)
- Weight
- Average: 460.328
Monoisotopic: 460.074542529 - Chemical Formula
- C21H14F6O5
- Synonyms
- Tecarfarin
- External IDs
- Ati 5923
- ATI-5923
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Tecarfarin. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Tecarfarin. Dexmethylphenidate The serum concentration of the active metabolites of Tecarfarin can be increased when Tecarfarin is used in combination with Dexmethylphenidate. Doxycycline The therapeutic efficacy of Tecarfarin can be increased when used in combination with Doxycycline. Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Tecarfarin. Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Tecarfarin. Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Tecarfarin. Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Tecarfarin. Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Tecarfarin. Lepirudin The risk or severity of bleeding can be increased when Tecarfarin is combined with Lepirudin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Coumarins and derivatives
- Sub Class
- Hydroxycoumarins
- Direct Parent
- 4-hydroxycoumarins
- Alternative Parents
- Benzoic acid esters / 1-benzopyrans / Benzoyl derivatives / Pyranones and derivatives / Vinylogous acids / Heteroaromatic compounds / Lactones / Carboxylic acid esters / Oxacyclic compounds / Organooxygen compounds show 4 more
- Substituents
- 1-benzopyran / 4-hydroxycoumarin / Alkyl fluoride / Alkyl halide / Aromatic heteropolycyclic compound / Benzenoid / Benzoate ester / Benzoic acid or derivatives / Benzopyran / Benzoyl show 16 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- WN1479YT50
- CAS number
- 867257-26-9
- InChI Key
- QFLNTQDOVCLQKW-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
- IUPAC Name
- 1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoate
- SMILES
- CC(OC(=O)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1)(C(F)(F)F)C(F)(F)F
References
- General References
- Not Available
- External Links
- PubChem Compound
- 54718618
- PubChem Substance
- 347828992
- ChemSpider
- 26467760
- ChEMBL
- CHEMBL2105664
- Wikipedia
- Tecarfarin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Unknown Status Treatment Thromboembolism / Thrombosis 1 2 Completed Treatment Atrial Fibrillation 1 2, 3 Unknown Status Treatment Atrial Fibrillation / Atrial Flutter / Cardiomyopathy / Myocardial Infarction / Venous Thromboembolism Diseases 1 1 Completed Basic Science Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin 1 1 Enrolling by Invitation Basic Science Healthy Chinese Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0026 mg/mL ALOGPS logP 4.71 ALOGPS logP 5.26 Chemaxon logS -5.2 ALOGPS pKa (Strongest Acidic) 5.13 Chemaxon pKa (Strongest Basic) -6.7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 72.83 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 99.73 m3·mol-1 Chemaxon Polarizability 37.11 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 21, 2016 00:31 / Updated at February 21, 2021 18:54